The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000427370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/03/2026
Date registered
Help: Date registered
7/04/2026
Date last updated
Help: Date last updated
2/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Concussion Incidence with Gamegear Nodal Impact Attenuation Headgear: A Multistate Randomised Crossover Clinical Trial in Australian Collision Sports
Scientific title
Concussion Incidence with Gamegear Nodal Impact Attenuation Headgear: A Multistate Randomised Crossover Clinical Trial in Australian Collision Sports
Additional trial identifiers [1] 316653 0
None
Universal Trial Number (UTN)
U1111-1336-4157
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Concussion 340873 0
Condition category
Condition code
Neurological 337032 337032 0 0
Other neurological disorders
Injuries and Accidents 337033 337033 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
GameGear Nodal Impact Attenuation padded headgear: All participants allocated to the intervention will wear the same model of commercially manufactured GameGear Nodal Impact Attenuation padded headgear, with size adjusted for individual fit. Headgear will be fitted pre-season by research staff, and participants will be encouraged to trial the headgear during at least one training session before match use to confirm comfort and fit. Headgear use is randomised at the team-week level within a randomised crossover design. Over one competitive season, participants will contribute up to five headgear-ON and five headgear-OFF match exposures, subject to match participation and availability. During allocated headgear-ON matches, the headgear is intended to be worn for the full duration of the match unless discontinued earlier because of discomfort or fit issues. Match duration is expected to range from approximately 80 to 140 minutes depending on the code and competition. Adherence will be supported by issue of headgear in allocated headgear-ON matches and assessed by post-match verification of compliance using match recordings/video review, supplemented by team records and participant post-match questionnaires.
A subset of up to 150 participants will also take part in the instrumented mouthguard component. These participants will undergo a dental scan by a licensed dental technician to produce a custom-fit Nexus Gen III instrumented mouthguard, will be asked to trial the mouthguard during training before study commencement, and will wear it during matches across one season to record head impact kinematics. The instrumented mouthguard subgroup will be recruited from selected teams based on logistical feasibility and to support appropriate sport, sex and age representation. Within these teams, eligible consenting participants may elect to take part in the mouthguard component. Eligibility for the mouthguard component includes having stable dentition suitable for mouthguard fitting, and excludes individuals with active orthodontic treatment that result in ongoing tooth movement during the study period.
Intervention code [1] 333330 0
Prevention
Intervention code [2] 333518 0
Treatment: Devices
Description of the comparator or control
During randomly allocated headgear-OFF matches, participants will play under usual competition conditions without wearing the GameGear Nodal Impact Attenuation (NIA) padded headgear. This is the control exposure in the randomised crossover trial.
Control group
Active

Outcomes
Primary outcome [1] 344545 0
Incidence of neurologist-diagnosed sport-related concussion
Timepoint [1] 344545 0
During the competitive season, with suspected cases reviewed 24–48 hours post-match
Primary outcome [2] 344546 0
Incidence of acute injury signs in athletes diagnosed with concussion
Timepoint [2] 344546 0
At the time of injury, with adjudication completed during early post-injury review
Primary outcome [3] 344859 0
Symptom burden in athletes diagnosed with concussion
Timepoint [3] 344859 0
Primary timepoint: 24 hours post-injury. Additional timepoints: 3, 7, 14, 21 and 28 days post-injury.
Secondary outcome [1] 458933 0
Incidence of neurologist-diagnosed mild traumatic brain injury
Timepoint [1] 458933 0
During the competitive season, with suspected concussion cases reviewed 24–48 hours post-match
Secondary outcome [2] 458934 0
Head impact biomechanics
Timepoint [2] 458934 0
During selected matches across the competitive season
Secondary outcome [3] 458935 0
Plasma glial fibrillary acidic protein concentration in athletes diagnosed with concussion
Timepoint [3] 458935 0
Approximately 24 hours post-injury
Secondary outcome [4] 458936 0
Plasma glial fibrillary acidic protein concentration in athletes after non-concussive match exposure
Timepoint [4] 458936 0
Approximately 24 hours post-match

Eligibility
Key inclusion criteria
Eligible participants are athletes aged 15 years and over who are coach-nominated first-team players from recruited teams in participating collision-sport competitions, and who provide written informed consent to participate. Participating teams must have appropriate match-day staff and routine match video capture/filmed matches to support study procedures. For participants aged 15–17 years, parental/guardian written consent and participant assent are required
Minimum age
15 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Key exclusion criteria are: concussion within the previous 6 months; history of moderate to severe brain injury; medical conditions that may contribute to neurological impairment (e.g. epilepsy, significant cognitive impairment, structural brain abnormality, multiple sclerosis or dementia); pregnancy or breastfeeding; current anticoagulant or antiplatelet use; venepuncture not feasible; and regular or intended use of protective headgear during the study period. For the instrumented mouthguard subgroup only, exclusion criteria also include current or permanent dental or orthodontic appliances affecting the upper dentition (e.g. braces)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed. Teams are provided with their headgear-ON and headgear-OFF schedule in advance.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated permuted block randomisation schedule is used to allocate team competition weeks to headgear-ON or headgear-OFF conditions in a balanced 1:1 manner across the study period
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD,VIC

Funding & Sponsors
Funding source category [1] 321264 0
Commercial sector/Industry
Name [1] 321264 0
GameGear
Country [1] 321264 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 323983 0
None
Name [1] 323983 0
Address [1] 323983 0
Country [1] 323983 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319792 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319792 0
Ethics committee country [1] 319792 0
Australia
Date submitted for ethics approval [1] 319792 0
07/01/2026
Approval date [1] 319792 0
20/02/2026
Ethics approval number [1] 319792 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148418 0
A/Prof Stuart McDonald
Address 148418 0
The Alfred Centre L6, 99 Commercial Rd, Melbourne VIC 3004
Country 148418 0
Australia
Phone 148418 0
+61 3 9903 0203
Fax 148418 0
Email 148418 0
Contact person for public queries
Name 148419 0
Stuart McDonald
Address 148419 0
The Alfred Centre L6, 99 Commercial Rd, Melbourne VIC 3004
Country 148419 0
Australia
Phone 148419 0
+61 3 9903 0203
Fax 148419 0
Email 148419 0
Contact person for scientific queries
Name 148420 0
Stuart McDonald
Address 148420 0
The Alfred Centre L6, 99 Commercial Rd, Melbourne VIC 3004
Country 148420 0
Australia
Phone 148420 0
+61 3 9903 0203
Fax 148420 0
Email 148420 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.